// App-Quantinova.ai

POS0196 (2021) : UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY

Researchers

Presenter

  • P. J. Mease

Principal Investigators

  • A. Lertratanakul

  • K. Papp

  • F. Van den Bosch

  • S. Tsuji

  • E. Dokoupilova

  • M. Keiserman

  • X. Bu

  • L. Chen

  • P. Zueger

  • E. Mcdearmon-Blondell

  • A. Pangan

  • W. Tillett

Medical Centers

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • AbbVie Inc, Immunology, Illinois, United States of America

  • K Papp Clinical Research, Probity Medical Research, Waterloo, Canada

  • Ghent University and VIB Centre for Inflammation Research, Department of Internal Medicine and Paediatrics, Ghent, Belgium

  • National Hospital Organization, Osaka Minami Medical Center, Orthopaedics/Rheumatology, Osaka, Japan

  • Medical Plus, s.r.o., Uherske Hradiste, Masaryk University, Pharmaceutical Technology, Brno, Czech Republic

  • Pontificial Catholic Univ School of Med, Port Alegre, Brazil

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

Locations

  • United States

  • Canada

  • Belgium

  • Japan

  • Czech Republic

  • Brazil

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Plasminogen Activator, Urokinase

  • Malondialdehyde

  • Albumin/creatinine

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved